- Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
- Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
- Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
- Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
- Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
- Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
- Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
- Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
- Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
- Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
More ▼
Key statistics
On Thursday, Lumos Pharma Inc (LUMO:NMQ) closed at 2.50, 24.38% above the 52 week low of 2.01 set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.48 |
---|---|
High | 2.63 |
Low | 2.35 |
Bid | 2.50 |
Offer | 2.55 |
Previous close | 2.57 |
Average volume | 40.83k |
---|---|
Shares outstanding | 8.12m |
Free float | 5.29m |
P/E (TTM) | -- |
Market cap | 20.86m USD |
EPS (TTM) | -4.59 USD |
Data delayed at least 15 minutes, as of May 23 2024 20:56 BST.
More ▼